share_log

Bellerophon Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Janus Henderson Group plc(5.1%),Janus Henderson Biotech Innovation Master Fund Ltd(5.1%)

Bellerophon Therapeutics | SC 13G:超過5%持股股東披露文件-Janus Henderson Group plc(5.1%),Janus Henderson Biotech Innovation Master Fund Ltd(5.1%)

SEC announcement ·  2023/05/25 11:17
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息